Publication

Article

Digital Edition

Ophthalmology Times: July 15, 2020
Volume45
Issue 12

Diagnosing a 'down looker'

Author(s):

Jon Carter

Diagnosing a 'down looker'

Diagnosing a 'down looker'


See more Optic Relief content by Jon Carter

Download Issue PDF
Articles in this issue
Aspheric, aberration-free IOL leverages technology for performance
Aspheric, aberration-free IOL leverages technology for performance
Emerging opportunities — and risks — with telehealth in a pandemic
Emerging opportunities — and risks — with telehealth in a pandemic
Figure 1: The Tecnis Toric II lens has an edge of the haptic that is unpolished to create more friction
Toric stability: A minor change with a major impact for patients
Teaching AI algorithms to identify corneal pathology: The future is now
Teaching AI algorithms to identify corneal pathology: The future is now
Diagnosing a 'down looker'
Diagnosing a 'down looker'
A hands-free treatment regimen is found to be safe and effective compared with a conventional eyedrop regimen.
Dropless, hands-free regimen key for patients
Amid pandemic, friendly bugs can help protect the eye from infection
Amid pandemic, friendly bugs can help protect the eye from infection
(Figure 1) These images show the remaining island of residual tissue targeted by gene therapy at treatment. The image at left is 1 week after treatment. (Photos courtesy of M. Dominik Fischer, MD, PhD)
Gene therapy offers hope for choroideremia
Machine-learning algorithms could help predict course of NPDR
Machine-learning algorithms could help predict course of NPDR
Thyroid eye disease: Not limited to visual impairment
Thyroid eye disease: Not limited to visual impairment
Beating burnout with camaraderie
Beating burnout with camaraderie
Themistocles: Everyone's second chance
Themistocles: Everyone's second chance
IOP homeostasis in glaucoma: Looking below the surface
IOP homeostasis in glaucoma: Looking below the surface
Clearing hurdles to large scale telemedicine adoption
Clearing hurdles to large scale telemedicine adoption
A patient's vision loss leads to another diagnosis
The eyes offer conjunctival clue to COVID-19

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)
June 27th 2025

Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Qlaris Bio to present new data on QLS-111 at the 2025 World Glaucoma Congress
June 26th 2025

Qlaris Bio to present new data on QLS-111 at the 2025 World Glaucoma Congress

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

36-month results from phase 1/2a clinical study of RG6501 released
June 26th 2025

36-month results from phase 1/2a clinical study of RG6501 released

Opus Genetics reports positive phase 3 results for phentolamine ophthalmic solution 0.75%
June 26th 2025

Opus Genetics reports positive phase 3 results for phentolamine ophthalmic solution 0.75%

© 2025 MJH Life Sciences

All rights reserved.